Dasatinib Monohydrate

Name: Dasatinib Monohydrate
Brand: Selleck Chemicals
SKU: S7782
Rating: 5 (205 reviews)

For research use only.

Catalog No.S7782 Synonyms: BMS-354825 Monohydrate

205 publications

Dasatinib Monohydrate Chemical Structure

CAS No. 863127-77-9

Dasatinib Monohydrate (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

Selleck's Dasatinib Monohydrate has been cited by 205 publications

Nature, 2020, 10.1038/s41586-020-2884-6

PubMed: 33149299 ( click the link to review the publication )

Science, 2020, 370(6513)eabc2754

PubMed: 33004676 ( click the link to review the publication )

Nature, 2016, 534(7607):341-6

PubMed: 27281222 ( click the link to review the publication )

Cell, 2012, 21;151(7):1457-73.

PubMed: 23245941 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Acta Neuropathol, 2021, 10.1007/s00401-021-02327-x

PubMed: 34046693 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3705

PubMed: 34140493 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab538

PubMed: 34181735 ( click the link to review the publication )

Theranostics, 2021, 11(4):1918-1936

PubMed: 33408789 ( click the link to review the publication )

PLoS Pathog, 2021, 17(8):e1009868

PubMed: 34415956 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3635

PubMed: 34298852 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):139

PubMed: 34117218 ( click the link to review the publication )

Cell Death Dis, 2021, 12(9):827

PubMed: 34480020 ( click the link to review the publication )

FASEB J, 2021, 35(1):e21229

PubMed: 33368613 ( click the link to review the publication )

Mol Oncol, 2021, 15(2):710-724

PubMed: 33155364 ( click the link to review the publication )

Biochem Pharmacol, 2021, 192:114666

PubMed: 34186065 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Proteomics, 2021, 10.1002/pmic.202000251

PubMed: 34151541 ( click the link to review the publication )

J Pathol Clin Res, 2021, 10.1002/cjp2.211

PubMed: 33890726 ( click the link to review the publication )

Cardiovasc Toxicol, 2021, 10.1007/s12012-021-09672-z

PubMed: 34269955 ( click the link to review the publication )

Ann Hematol, 2021, 10.1007/s00277-020-04357-z

PubMed: 34110462 ( click the link to review the publication )

Environ Toxicol Pharmacol, 2021, 84:103625

PubMed: 33617955 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 571:174-180

PubMed: 34330061 ( click the link to review the publication )
Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

J Virol, 2021, JVI.00180-21

PubMed: 33597213 ( click the link to review the publication )

eNeuro, 2021, ENEURO.0053-21.2021

PubMed: 33811086 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)740

PubMed: 33578955 ( click the link to review the publication )

Blood, 2020, 8 pii: blood

PubMed: 32270193 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Neuro Oncol, 2020, 15;22(4):493-504

PubMed: 31883012 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 30;251:120077

PubMed: 32388166 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):3951-3963 e4

PubMed: 32209458 ( click the link to review the publication )

Elife, 2020, 9e60470

PubMed: 33226337 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

Oncogene, 2020, 39(20):4045-4060

PubMed: 32214198 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 25;12(5)

PubMed: 32344828 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Breast Cancer Res, 2020, 15;22(1):37

PubMed: 32295603 ( click the link to review the publication )

Cell Death Discov, 2020, 15;6:36

PubMed: 32435511 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

Br J Haematol, 2020, 10.1111/bjh.17139

PubMed: 33216963 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )
Mol Cancer Res, 2020, 18(7):1004-1017

PubMed: 32238439 ( click the link to review the publication )

Microb Cell Fact, 2020, 20;19(1):74

PubMed: 32197603 ( click the link to review the publication )

Biochem Pharmacol, 2020, 30;177:113941

PubMed: 32240650 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9276

PubMed: 33291786 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Am J Pathol, 2020, S0002-9440(20)30550-2

PubMed: 33307038 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015489

PubMed: 33037073 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Breast Cancer Res Treat, 2020, 179(2):337-347

PubMed: 31655920 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Biomol Ther (Seoul), 2020, 9

PubMed: 32268657 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

Blood Adv, 2020, 4(24):6106-6116

PubMed: 33351104 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):145-154

PubMed: 32565942 ( click the link to review the publication )

J Clin Invest, 2020, 133310

PubMed: 32603316 ( click the link to review the publication )

Hemasphere, 2020, 4(6):e497

PubMed: 33196013 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(12):e12391

PubMed: 33231937 ( click the link to review the publication )

Front Microbiol, 2020, 10:2936

PubMed: 32038511 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3416

PubMed: 32651372 ( click the link to review the publication )
Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Oncogene, 2019, 38(29):5805-5816

PubMed: 31235784 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1945

PubMed: 31817360 ( click the link to review the publication )

Cell Death Dis, 2019,

PubMed: 30988279 ( click the link to review the publication )

J Clin Med, 2019, 8(4)E455

PubMed: 30987403 ( click the link to review the publication )

Pharmacol Res, 2019, 147:104357

PubMed: 31356863 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17104

PubMed: 31745115 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(9)

PubMed: 31461998 ( click the link to review the publication )

J Biol Chem, 2019, 294(22):8732-8744

PubMed: 30996006 ( click the link to review the publication )

J Acquir Immune Defic Syndr, 2019, 82(4):407-415

PubMed: 31658184 ( click the link to review the publication )

Exp Hematol, 2019, 77:36-40.e2

PubMed: 31493432 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):4449-4456

PubMed: 31611954 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Blood, 2018, 131(14):1532-1544

PubMed: 29437554 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2590

PubMed: 29968724 ( click the link to review the publication )

Oncogene, 2018, 37(38):5221-5232

PubMed: 29849118 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):130

PubMed: 30359299 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Front Immunol, 2018, 9:8

PubMed: 29403492 ( click the link to review the publication )

Front Immunol, 2018, 9:2033

PubMed: 30283437 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Oral Oncol, 2018, 78:56-63

PubMed: 29496059 ( click the link to review the publication )

J Immunol, 2018,

PubMed: 29351998 ( click the link to review the publication )

J Cell Sci, 2018, 131(22)jcs221788

PubMed: 30404826 ( click the link to review the publication )
Sci Rep, 2018, 8(1):584

PubMed: 29330550 ( click the link to review the publication )

Apoptosis, 2018, 23(5-6):343-355

PubMed: 29740790 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1081

PubMed: 30319416 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 502(1):110-115

PubMed: 29787755 ( click the link to review the publication )

Cell Biol Int, 2018,

PubMed: 29885023 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6831-6838

PubMed: 29731862 ( click the link to review the publication )

J Pharmacokinet Pharmacodyn, 2018, 45(3):401-418

PubMed: 29446053 ( click the link to review the publication )

Oncotarget, 2018, 9(5):5545-5561

PubMed: 29464017 ( click the link to review the publication )

Leukemia, 2017, 31(5):1253-1254

PubMed: 28465516 ( click the link to review the publication )

Cancer Res, 2017,

PubMed: 27821486 ( click the link to review the publication )

Int J Cancer, 2017, 140(5):1173-1185

PubMed: 27798955 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28638122 ( click the link to review the publication )

Front Mol Neurosci, 2017, 10:418

PubMed: 29326548 ( click the link to review the publication )

PLoS ONE, 2017,

PubMed: 28945796 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(8):1903-1913

PubMed: 27931141 ( click the link to review the publication )

Exp Ther Med, 2017,

PubMed: 28810597 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Oncotarget, 2017, 8(27):43662-43677

PubMed: 28599273 ( click the link to review the publication )

EMBO Mol Med, 2016, 1;8(2):105-16

PubMed: 26758680 ( click the link to review the publication )

Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

Sci Signal, 2016, 9(456):ra116

PubMed: 27899526 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1472-84

PubMed: 27364904 ( click the link to review the publication )
Hum Mol Genet, 2016, 25(2):266-74

PubMed: 26604135 ( click the link to review the publication )

Psychoneuroendocrinology, 2016, 66:138-49

PubMed: 26803529 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1862(11):2158-2167

PubMed: 27565738 ( click the link to review the publication )

Sci Rep, 2016, 6:26252

PubMed: 27188220 ( click the link to review the publication )

Mol Cell Endocrinol, 2016, 433:94-104

PubMed: 27267669 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45916-45925

PubMed: 27322141 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27602951 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27756880 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27687593 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016, 7(17):24483-94

PubMed: 27016416 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26623721 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Arterioscler Thromb Vasc Biol, 2015, 35(11):2326-35

PubMed: 26359510 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(15):4296-305

PubMed: 25948553 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: 25248068 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2015, 56(9):5457-64

PubMed: 26284551 ( click the link to review the publication )
Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

Exp Hematol, 2015,

PubMed: 25641047 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2014,

PubMed: 23318431 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1005

PubMed: 24434513 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Stem Cells, 2014, 32(9):2324-37

PubMed: 24806995 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 24196445 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10(11):2876-88

PubMed: 25099472 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Pharmacogenet Genomics, 2014, 24(1):52-61

PubMed: 24322003 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )
Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Proteomics, 2013, 13(23-24):3554-62

PubMed: 24167056 ( click the link to review the publication )

Cell Adh Migr, 2013, 7(4):362-9

PubMed: 23751956 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )
PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Oncotarget, 2012, 3(12):1557-65

PubMed: 23238683 ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(4):762-70

PubMed: 21106726 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Biochem Pharmacol, 2011, 82(10):1457-66

PubMed: 21664897 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Dasatinib Monohydrate (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
K562 cell	MmTLVJJwdGmoZYLheIlwdiCjc4PhfS=>	NGjqcmQ4OiCq	NWj1NoF1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NF0xNjByMTFOwG0>	NYP2[GJuOTV4MUW1NVI>
WiDr cell	MWfQdo9tcW[ncnH0bY9vKGG\|c3H5	NYXCd\|k1PzJiaB?=	NWr4clE2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDXbWRzKGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NF0xNjB3MjFOwG0>	MXOxOVYyPTVzMh?=
PC3 cell	NEH2d\|NRem:uaX\ldoF1cW:wIHHzd4F6	MVy3NkBp	NIHOXHRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB5MjDodpMtKEmFNUC9NE4xODl2IN88US=>	NGf0OZUyPTZzNUWxNi=>
MDA-MB-231 cell	NF3WW5RRem:uaX\ldoF1cW:wIHHzd4F6	NIDOfJc4OiCq	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgO\|IhcHK\|LDDJR\|UxRTBwMEGyJO69VQ>?	M3PNNVE2PjF3NUGy
M07ep210 cell	NEX0bo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1Ln[VQ5KGh?	Ml2zS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUVA4\XB{MUCgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFt\|SG30bJlucWSrbnWgeZB1[WunIHHzd4F6NCCLQ{WwQVAvODdibl2=	NYriOGVwOTd7NU[wPFA>
K562 cell	M1frdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MXe0PEBp	NX;ab21FT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUzV4MjDj[YxteyCjZoTldkA1QCCqcoOgZpkhYzOKXYTofY1q\GmwZTD1dJRic2ViYYPzZZktKEmFNUC9NE4xODFizszN	M1K1SVE4QTV4MEiw
M07e cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmPjOFghcA>?	M4rxUGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG0xP2ViY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHs{UF22aIntbYRqdmVidYD0ZYtmKGG\|c3H5MEBKSzVyPUCuNFAyOiEQvF2=	NVjhOWdtOTd7NU[wPFA>
K562 cell	NF3afWREgXSxdH;4bYNqfHliYYPzZZk>	M2foelczKGh?	MofuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT\|U3OiClZXzsd{Bi\nSncjC3NkBpenNiYomgW3NVNThicnXh[4VvfCCkYYPl[EBOXFRiYYPzZZktKEmFNUC9NVIvQDNizszN	NGPZVVUzOjJzN{i3Oy=>
U937 cell	NHHlXHVEgXSxdH;4bYNqfHliYYPzZZk>	MXW3NkBp	M1viPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXC16IILlZYdmdnRiYnHz[YQhVVSWIHHzd4F6NCCLQ{WwQVE{NjZ\|IN88US=>	NFXW[IgzOjJzN{i3Oy=>
K562 cell	MVzQdo9tcW[ncnH0bY9vKGG\|c3H5	MVS3NkBp	NUj2e3hjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyPUCuO{BvVQ>?	NIPHZ5QzOzV{MUCyNC=>
MDA-MB-435S cell	M3PWUXBzd2yrZnXyZZRqd25iYYPzZZk>	NYnO[XN1PzJiaB?=	MonKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuPDN3UzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVMvQSEQvF2=	Mn7uNlM2OjFyMkC=
NCI-H460 cell	MnXFVJJwdGmoZYLheIlwdiCjc4PhfS=>	NFjEOWQ4OiCq	M33BPWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg1PjBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME24Mlk6KM7:TR?=	M3XZclI{PTJzMEKw
NCI-H23 cell	NEnOSG9Rem:uaX\ldoF1cW:wIHHzd4F6	MXi3NkBp	MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3INlMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1{LkK3JO69VQ>?	MljLNlM2OjFyMkC=
A549 cell	NWTzNVJWWHKxbHnm[ZJifGmxbjDhd5NigQ>?	M4\aflczKGh?	NI\RVGNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zMj62OkDPxE1?	NXzsPYx2OjN3MkGwNlA>
T47D cell	MlO0VJJwdGmoZYLheIlwdiCjc4PhfS=>	NGTtZ4U4OiCq	M1XiemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVES3SEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwOTFOwG0>	NYTCOWdZOjN3MkGwNlA>
HCT116 cell	Mmq1VJJwdGmoZYLheIlwdiCjc4PhfS=>	NUiwPY9iPzJiaB?=	Ml\zRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1{LkOg{txO	NVPJ[2d1OjN3MkGwNlA>
MCF7 cells	MXHQdo9tcW[ncnH0bY9vKGG\|c3H5	MXu3NkBp	MkK0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:Oi53NzFOwG0>	NYSzVoduOjN3MkGwNlA>
RXF 393NL cell	NULQ[XJjS3m2b4TvfIlkcXS7IHHzd4F6	NHjrS3c1KGSjeYO=	NXLsTZpxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWliIIEO5N25NKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLDDJR\|UxRTJzLkegcm0>	MYSyN\|I2OzB5NB?=
PRXF DU145 cell	MUDDfZRwfG:6aXPpeJkh[XO\|YYm=	NF7NbZg1KGSjeYO=	NUXCeoZIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWFK[RjDEWVE1PSClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzygTWM2OD1yLkC2NlMh\|ryP	MlTtNlMzPTNyN{S=
LXFA 983L cell	MU\DfZRwfG:6aXPpeJkh[XO\|YYm=	NFWwc5M1KGSjeYO=	NVf0NW1xS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFiIQTC5PFNNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLDDJR\|UxRTV4LkWgcm0>	M3XB[VI{OjV\|MEe0
GXF251L cell	MULDfZRwfG:6aXPpeJkh[XO\|YYm=	MUW0JIRigXN?	NXj5cXAyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hT1iIMkWxUEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yxiSVO1NF0zNjJ3IN88US=>	MW[yN\|I2OzB5NB?=
CXF 1103L cell	MXHDfZRwfG:6aXPpeJkh[XO\|YYm=	MV:0JIRigXN?	M2frfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNZTiBzMUCzUEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yxiSVO1NF01NjN4IN88US=>	NXnaR2MzOjN{NUOwO\|Q>
PAXF 1657L cell	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=	NVLT[Jk2PCCmYYnz	MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQRXhHKDF4NUfMJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNCCLQ{WwQVAvOTJzIN88US=>	NV7y[ZZiOjN{NUOwO\|Q>
NCI-H1648 cell	M4Tkc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFTSXVZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY1QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwMEKwNVEh\|ryP	M1rLd3NCVkeHUh?=
NCI-H1838 cell	M1naPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUizPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzB5M{Og{txO	MYXTRW5ITVJ?
NCI-H2126 cell	NILNZo9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEfKcGxKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlEzPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwOEe1OVIh\|ryP	M33DZnNCVkeHUh?=
NCI-H2141 cell	NYXkTWFXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH7zbVhKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlE1OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJ2Lke3OVQh\|ryP	MmjkV2FPT0WU
NCI-H2107 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NW\VO3hRUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIyODdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Mz60PFQ4KM7:TR?=	MWTTRW5ITVJ?
NCI-H747 cell	MlfBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWrJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{S3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQDN4MjFOwG0>	Mkf3V2FPT0WU
NCI-H720 cell	M3[x[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{LDNWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3NlAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOC5{N{OzJO69VQ>?	MnG2V2FPT0WU
NKM-1 cell	M2TrWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NH;WV2xKdmirYnn0bY9vKG:oIHj1cYFvKE6NTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xMlMxQDV7IN88US=>	MkH1V2FPT0WU
NMC-G1 cell	M4S5cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVfJcohq[mm2aX;uJI9nKGi3bXHuJG5OSy2JMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6xNVYxPiEQvF2=	NX3VVZROW0GQR1XS
NTERA-S-cl-D1 cell	NEHNWmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVnJcohq[mm2aX;uJI9nKGi3bXHuJG5VTVKDLWOtZ4wuTDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMUKyPFMh\|ryP	M4DJ[3NCVkeHUh?=
OCI-AML2 cell	MlToS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJG9EUS2DTVyyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME21Mlg3OTV2IN88US=>	NFjuNXRUSU6JRWK=
OCUB-M cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEXVclBKdmirYnn0bY9vKG:oIHj1cYFvKE:FVVKtUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NU4xPDRzMjFOwG0>	Mn\1V2FPT0WU
OPM-2 cell	MmDSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWjIN4NUUW6qaXLpeIlwdiCxZjDoeY1idiCRUF2tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9OE4zPzZ6NTFOwG0>	MmDoV2FPT0WU
OS-RC-2 cell	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3HWbmlvcGmkaYTpc44hd2ZiaIXtZY4hV1NvUlOtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xOjB\|IN88US=>	M3zvTHNCVkeHUh?=
ONS-76 cell	M{jxUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NF7yVWJKdmirYnn0bY9vKG:oIHj1cYFvKE:QUz23OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE41Ojl3MTFOwG0>	M1m2U3NCVkeHUh?=
OVCAR-4 cell	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUPGZoE4UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjN5NEOzJO69VQ>?	MlzEV2FPT0WU
NCI-H446 cell	M{\qV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NG[1UllKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOFQ3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjZ{N{[g{txO	M2\ocHNCVkeHUh?=
NCI-H510A cell	NXHrTldjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NW\qWld7UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUyOEFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTF7LkO5O\|Mh\|ryP	MX7TRW5ITVJ?
PF-382 cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1rJRWlvcGmkaYTpc44hd2ZiaIXtZY4hWEZvM{iyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlE4Pjd6IN88US=>	M13pd3NCVkeHUh?=
NCI-H64 cell	NYi0d5ZMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlHJTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2yPU43OjV\|IN88US=>	NWXlNHlUW0GQR1XS
PSN1 cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NX35TFdxUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlA1PDd2IN88US=>	NHnKZ5RUSU6JRWK=
QIMR-WIL cell	M{O0ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2rUUGlvcGmkaYTpc44hd2ZiaIXtZY4hWUmPUj3XTWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvPzB4Mkmg{txO	Mnn0V2FPT0WU
RL95-2 cell	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWHZSJN4UW6qaXLpeIlwdiCxZjDoeY1idiCUTEm1MVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvOTB\|ODFOwG0>	M3fJeXNCVkeHUh?=
RCC10RGB cell	Mo\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVz2RVZrUW6qaXLpeIlwdiCxZjDoeY1idiCUQ1OxNHJISiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC52OUGxJO69VQ>?	MkPSV2FPT0WU
RKO cell	NUnvNVVnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH[2coJKdmirYnn0bY9vKG:oIHj1cYFvKFKNTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD61Nlk3PiEQvF2=	NV72W5NSW0GQR1XS
NCI-SNU-16 cell	MofIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnXFTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF05NjV4MUK4JO69VQ>?	NWr2NIFmW0GQR1XS
RPMI-6666 cell	Mo\xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3q0cWlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST22OlY3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF04NjJ5ME[3JO69VQ>?	MoHjV2FPT0WU
NEC8 cell	NX:xWpllT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXHnTHN1UW6qaXLpeIlwdiCxZjDoeY1idiCQRVO4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME20OE4{OzZizszN	M3exSnNCVkeHUh?=
RS4-11 cell	MmPDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnrhTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUeuOlU4QDdizszN	NGr1OJpUSU6JRWK=
RXF393 cell	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWrSb5MyUW6qaXLpeIlwdiCxZjDoeY1idiCUWF[zPVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvODJ\|NUeg{txO	NYe3UVZPW0GQR1XS
Raji cell	MkDZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmLDTY5pcWKrdHnvckBw\iCqdX3hckBT[WqrIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1zMz63OFk4KM7:TR?=	NEDNOI1USU6JRWK=
NOS-1 cell	NULRcVIyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4\vSGlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFA3OTJ7IN88US=>	NU\KcY5iW0GQR1XS
SBC-1 cell	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NF3OfJlKdmirYnn0bY9vKG:oIHj1cYFvKFOEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xMlU4QTh2IN88US=>	MojkV2FPT0WU
SF126 cell	M{TKOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M37nV2lvcGmkaYTpc44hd2ZiaIXtZY4hW0ZzMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuN\|U1OSEQvF2=	M{\U[nNCVkeHUh?=
SF539 cell	NXf1WYhUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFvWXoZKdmirYnn0bY9vKG:oIHj1cYFvKFOINUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xN{45PTV5IN88US=>	NXLhZXp4W0GQR1XS
SH-4 cell	M37PZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVLJcohq[mm2aX;uJI9nKGi3bXHuJHNJNTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMUi0NVMh\|ryP	MmO4V2FPT0WU
OMC-1 cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NI[0epZKdmirYnn0bY9vKG:oIHj1cYFvKE:PQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2yO{4yPDJ{IN88US=>	MoXLV2FPT0WU
SIG-M5 cell	MlfUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M33t[2lvcGmkaYTpc44hd2ZiaIXtZY4hW0mJLV21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME25MlAzPDl\|IN88US=>	MlLkV2FPT0WU
SJSA-1 cell	NI\Id3ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVTJcohq[mm2aX;uJI9nKGi3bXHuJHNLW0FvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;OD63NlgxPSEQvF2=	NUHuboVsW0GQR1XS
SK-LMS-1 cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWLJcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyPUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2zMlEyQDh4IN88US=>	MVjTRW5ITVJ?
SK-NEP-1 cell	NW\P[XlmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4G2XmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTlXQMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVgvQDlzNUWg{txO	M133dnNCVkeHUh?=
SKM-1 cell	NXvBd\|ZCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkLrTY5pcWKrdHnvckBw\iCqdX3hckBUU01vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;OT6wNVc{PCEQvF2=	NGjUeFdUSU6JRWK=
SK-PN-DW cell	Ml[4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmXRTY5pcWKrdHnvckBw\iCqdX3hckBUUy2STj3EW{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9N\|YvOTl2MzFOwG0>	MkXFV2FPT0WU
SK-UT-1 cell	Mn[0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEnlXXJKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVIvOTZ4OUOg{txO	NYO4UnR7W0GQR1XS
SNB75 cell	NHezcXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NU\nPHpVUW6qaXLpeIlwdiCxZjDoeY1idiCVTlK3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xPDR\|NTFOwG0>	M17wWHNCVkeHUh?=
REH cell	NHftSotIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYf0RnhEUW6qaXLpeIlwdiCxZjDoeY1idiCURVigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUKwMlY{PTdizszN	NH34eGRUSU6JRWK=
SNU-C2B cell	MljaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWrYOldNUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtR\|JDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0yNjNyNUi5JO69VQ>?	NH\qR2lUSU6JRWK=
RPMI-8866 cell	M{LsXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUfJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvOEi2OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NVcvPDR3NTFOwG0>	MVrTRW5ITVJ?
SW872 cell	NUfsb3BIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkK3TY5pcWKrdHnvckBw\iCqdX3hckBUXzh5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wOFE3OSEQvF2=	NFvaTYhUSU6JRWK=
SW962 cell	M3zu[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{fDUWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNVEzQTJizszN	MlLrV2FPT0WU
SF268 cell	NXnhdY1NT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHizeJlKdmirYnn0bY9vKG:oIHj1cYFvKFOIMk[4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlE4PDB2IN88US=>	NGPUOWRUSU6JRWK=
TE-1 cell	NUXYbnU2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mn3YTY5pcWKrdHnvckBw\iCqdX3hckBVTS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkGwOVQh\|ryP	NVPn[Y9iW0GQR1XS
8-MG-BA cell	NX65eJRvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGj1W5NKdmirYnn0bY9vKG:oIHj1cYFvKDhvTVetRmEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvOTV2NUig{txO	NXv2bJd[W0GQR1XS
A101D cell	NHjYNHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUDrS5VxUW6qaXLpeIlwdiCxZjDoeY1idiCDMUCxSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NU4xOzB2MzFOwG0>	NEe3bJpUSU6JRWK=
A253 cell	NEHkbHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVf4OGFHUW6qaXLpeIlwdiCxZjDoeY1idiCDMkWzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2zMlc{OjR4IN88US=>	MX3TRW5ITVJ?
A3-KAW cell	NFzUTotIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUDJcohq[mm2aX;uJI9nKGi3bXHuJGE{NUuDVzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD65PFQ2OiEQvF2=	Mkm0V2FPT0WU
A4-Fuk cell	MmfpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGrEdmRKdmirYnn0bY9vKG:oIHj1cYFvKEF2LV\1b{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9N\|gvOTByOTFOwG0>	NXrEPHM6W0GQR1XS
A388 cell	MoW0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{S2SmlvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wOVA6PSEQvF2=	M{e3bXNCVkeHUh?=
ACN cell	MkTHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlG2TY5pcWKrdHnvckBw\iCqdX3hckBCS05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTFwOEKyOVIh\|ryP	NGO3PW5USU6JRWK=
A704 cell	M2X5bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn;HTY5pcWKrdHnvckBw\iCqdX3hckBCPzB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCxOFkyKM7:TR?=	NF3QbmZUSU6JRWK=
ALL-PO cell	MnT1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4[0R2lvcGmkaYTpc44hd2ZiaIXtZY4hSUyOLWDPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xNE44QTN6IN88US=>	M4DwPHNCVkeHUh?=
ARH-77 cell	NFjrSJpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mn7iTY5pcWKrdHnvckBw\iCqdX3hckBCWkhvN{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUOuOFY6OTVizszN	MX;TRW5ITVJ?
SR cell	NXPOeXV7T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVzJcohq[mm2aX;uJI9nKGi3bXHuJHNTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF01NjR7OUW0JO69VQ>?	NWHtU4EzW0GQR1XS
BB65-RCC cell	NYX0OIgzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnfDTY5pcWKrdHnvckBw\iCqdX3hckBDSjZ3LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xQDJ{NzFOwG0>	M3f3S3NCVkeHUh?=
BB49-HNC cell	NUPu[2JXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYfGT5lnUW6qaXLpeIlwdiCxZjDoeY1idiCEQkS5MWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC5\|OEW5PUDPxE1?	M2jkcHNCVkeHUh?=
BC-1 cell	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUDoPHNZUW6qaXLpeIlwdiCxZjDoeY1idiCEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2yPE43PTFizszN	NELudmZUSU6JRWK=
BC-3 cell	M4\Ne2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWHJcohq[mm2aX;uJI9nKGi3bXHuJGJENTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTF{LkGxN\|gh\|ryP	Ml3vV2FPT0WU
BL-41 cell	NUPDR4drT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mn\KTY5pcWKrdHnvckBw\iCqdX3hckBDVC12MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6yPVEzOyEQvF2=	MXTTRW5ITVJ?
BL-70 cell	MlfES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MknUTY5pcWKrdHnvckBw\iCqdX3hckBDVC15MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wNFAxODB6MkG4JO69VQ>?	M4PsWHNCVkeHUh?=
SW684 cell	NIWwcnZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4n3TmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4OESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuN\|Q6QCEQvF2=	NWPJZnlYW0GQR1XS
BOKU cell	NHLDT3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlfMTY5pcWKrdHnvckBw\iCqdX3hckBDV0uXIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkS5NVM{KM7:TR?=	M2PLUXNCVkeHUh?=
SW954 cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVfJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTV2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCyPVI4KM7:TR?=	MkW1V2FPT0WU
C2BBe1 cell	MoS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEnHc3dKdmirYnn0bY9vKG:oIHj1cYFvKEN{QlLlNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xQDNyODFOwG0>	M4P4WHNCVkeHUh?=
BV-173 cell	MnezS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3HqSmlvcGmkaYTpc44hd2ZiaIXtZY4hSlZvMUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlAxODByMEGwPUDPxE1?	MYXTRW5ITVJ?
Becker cell	MmrUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mmi2TY5pcWKrdHnvckBw\iCqdX3hckBD\WOtZYKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFMxODNizszN	NV[0ZYF3W0GQR1XS
SW982 cell	NX7SPVY6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mn;ITY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wNVEyPSEQvF2=	NUfoR5NxW0GQR1XS
697 cell	MlHWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NH\MXY5KdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6xPVk5PyEQvF2=	NHnQeJhUSU6JRWK=
TE-15 cell	M3j0OGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYjJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTF3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCwOVg6OSEQvF2=	NXzMUWYxW0GQR1XS
TE-11 cell	NWXNZ5hlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoT1TY5pcWKrdHnvckBw\iCqdX3hckBVTS1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wO\|g2QCEQvF2=	MofEV2FPT0WU
TE-5 cell	MnezS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVnubmdMUW6qaXLpeIlwdiCxZjDoeY1idiCWRT21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xMlc6OTN7IN88US=>	NWGzb2x5W0GQR1XS
TE-6 cell	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUG0U3B5UW6qaXLpeIlwdiCxZjDoeY1idiCWRT22JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xMlIyOjJ4IN88US=>	NIDwUZFUSU6JRWK=
TE-9 cell	M4D1Wmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2Tud2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvOTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD64O\|U{OiEQvF2=	M3rwOHNCVkeHUh?=
TGBC24TKB cell	NVnFfGFUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIXTOIZKdmirYnn0bY9vKG:oIHj1cYFvKFSJQlOyOHRMSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC5yNEe2NUDPxE1?	NEHsbHVUSU6JRWK=
TGW cell	MkfVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NH;V[oZKdmirYnn0bY9vKG:oIHj1cYFvKFSJVzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MUGuNlgzQCEQvF2=	MoHnV2FPT0WU
TK10 cell	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2HoTGlvcGmkaYTpc44hd2ZiaIXtZY4hXEtzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wNVE4PCEQvF2=	NVO2Z5JjW0GQR1XS
TGBC1TKB cell	M2\1Umdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkfSTY5pcWKrdHnvckBw\iCqdX3hckBVT0KFMWTLRkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xPjF4NDFOwG0>	NYXyellsW0GQR1XS
A498 cell	M3rUUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX73TZNzUW6qaXLpeIlwdiCxZjDoeY1idiCDNEm4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlA4Ojh2IN88US=>	MWTTRW5ITVJ?
UACC-257 cell	NXLBdHpqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mm[2TY5pcWKrdHnvckBw\iCqdX3hckBWSUOFLUK1O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NVIvQTF7ODFOwG0>	M1fkb3NCVkeHUh?=
U-87-MG cell	M4Xr[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHvYcY9KdmirYnn0bY9vKG:oIHj1cYFvKFVvOEetUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVMxNjd4NjFOwG0>	M3:wOnNCVkeHUh?=
BB30-HNC cell	NX3GWXJ7T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1m1UWlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ\|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvODV2M{eg{txO	Ml3ZV2FPT0WU
no-10 cell	NILiNYFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlzGTY5pcWKrdHnvckBw\iCqdX3hckBvdy1zMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6zNVk{OSEQvF2=	MXnTRW5ITVJ?
CAS-1 cell	NVf5O\|ZwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUnFOG5HUW6qaXLpeIlwdiCxZjDoeY1idiCFQWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NU41ODl7MjFOwG0>	MYTTRW5ITVJ?
CGTH-W-1 cell	M3O0emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2rGXWlvcGmkaYTpc44hd2ZiaIXtZY4hS0eWSD3XMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvODN3NEig{txO	NXLTeGVZW0GQR1XS
TE-10 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFnqZ4hKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlA3OzV5IN88US=>	NVzkUmZiW0GQR1XS
COLO-684 cell	NYqwS\|NiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWHTdZEzUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:PDZwMkK1PEDPxE1?	M3rQbnNCVkeHUh?=
TE-12 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1rUcWlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFE5PjFizszN	MY\TRW5ITVJ?
COR-L279 cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MknHTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEK3PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9OFAvOjh3MjFOwG0>	NUHi[2o1W0GQR1XS
TE-8 cell	MnizS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1i0RmlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wNVU4PiEQvF2=	NGnLTGxUSU6JRWK=
CP66-MEL cell	NYTpXGxoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFrWVnBKdmirYnn0bY9vKG:oIHj1cYFvKEOSNk[tUWVNKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjF7NUOxJO69VQ>?	MX;TRW5ITVJ?
CTV-1 cell	NF\Vc2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M33oXGlvcGmkaYTpc44hd2ZiaIXtZY4hS1SYLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFAxODRyM{[g{txO	NYPGOldVW0GQR1XS
VA-ES-BJ cell	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M37iTWlvcGmkaYTpc44hd2ZiaIXtZY4hXkFvRWOtRmoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvODN7MEKg{txO	M3zVcHNCVkeHUh?=
D-263MG cell	NHf2fYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHvnOJlKdmirYnn0bY9vKG:oIHj1cYFvKERvMk[zUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvOzZ{MkSg{txO	MWnTRW5ITVJ?
D-336MG cell	NFSwUVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYfJcohq[mm2aX;uJI9nKGi3bXHuJGQuOzN4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFA3Ojl6IN88US=>	Mn\LV2FPT0WU
D-502MG cell	NWTld2NJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFjjVmFKdmirYnn0bY9vKG:oIHj1cYFvKERvNUCyUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVEvOjN\|N{[g{txO	NYi0XWlqW0GQR1XS
DJM-1 cell	NVO1R29qT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1vhWmlvcGmkaYTpc44hd2ZiaIXtZY4hTEqPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPU[uOFg2PThizszN	NX:3Wm5UW0GQR1XS
no-11 cell	NXjvRmNNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVTJcohq[mm2aX;uJI9nKGi3bXHuJI5wNTFzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkWwNlI5KM7:TR?=	M17udXNCVkeHUh?=
DMS-153 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2XuUGlvcGmkaYTpc44hd2ZiaIXtZY4hTE2VLUG1N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NVQvODB{ODFOwG0>	NGTkVWFUSU6JRWK=
DSH1 cell	NV32fGo5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NE\ObYFKdmirYnn0bY9vKG:oIHj1cYFvKESVSEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNlQxODFizszN	M4\0[nNCVkeHUh?=
DU-4475 cell	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXTJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTR2N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUiuNlE3PTJizszN	MXzTRW5ITVJ?
EB-3 cell	NWj0c5NiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGVDNTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTN2LkOxNVgh\|ryP	MYnTRW5ITVJ?
EHEB cell	MmfJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NF3Ud2NKdmirYnn0bY9vKG:oIHj1cYFvKEWKRVKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUGwMlA3PTZizszN	M4nKVXNCVkeHUh?=
COLO-829 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYjMPGlYUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVgzQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC5zMkKxN{DPxE1?	M4rQbHNCVkeHUh?=
CP67-MEL cell	NGjHfW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVflS2NJUW6qaXLpeIlwdiCxZjDoeY1idiCFUE[3MW1GVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC5{MES4PEDPxE1?	M2XB[HNCVkeHUh?=
ES8 cell	M{LLN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWHMeJM2UW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUOyMlEzPTJizszN	Mmj2V2FPT0WU
EVSA-T cell	Mni4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVPJcohq[mm2aX;uJI9nKGi3bXHuJGVXW0FvVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;OT6yO\|c6OyEQvF2=	MmrMV2FPT0WU
ES4 cell	M3nXTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYfJcohq[mm2aX;uJI9nKGi3bXHuJGVUPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OS5yNUG0OUDPxE1?	M3rPXnNCVkeHUh?=
ETK-1 cell	M1O1VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVfvTpEyUW6qaXLpeIlwdiCxZjDoeY1idiCHVFutNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xOjh\|MjFOwG0>	M1XENXNCVkeHUh?=
ES6 cell	NFTPTG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGVUPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC5yM{G5N{DPxE1?	M2LzVHNCVkeHUh?=
EW-24 cell	M1:xVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{DtN2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuO\|gyPjVizszN	NFvYfJdUSU6JRWK=
EoL-1-cell cell	NX;JN5c3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{nqWWlvcGmkaYTpc44hd2ZiaIXtZY4hTW:OLUGtZ4VtdCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC5yMECwNVMxQSEQvF2=	MmHVV2FPT0WU
Calu-6 cell	NUTa[Yx[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFj2[GdKdmirYnn0bY9vKG:oIHj1cYFvKEOjbIWtOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9N{4xPTd2MTFOwG0>	M3S4TXNCVkeHUh?=
GAK cell	NF3kUZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGdCUyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OzFwMk[4OkDPxE1?	MYjTRW5ITVJ?
D-247MG cell	NWnUNHViT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoCwTY5pcWKrdHnvckBw\iCqdX3hckBFNTJ2N13HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME22MlEzPTF7IN88US=>	MV\TRW5ITVJ?
GB-1 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXXJcohq[mm2aX;uJI9nKGi3bXHuJGdDNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMEKxOVch\|ryP	MYjTRW5ITVJ?
GI-ME-N cell	NGW2cZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkThTY5pcWKrdHnvckBw\iCqdX3hckBIUS2PRT3OJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlA3OTF6IN88US=>	M2LOenNCVkeHUh?=
GCIY cell	NYW2RmQyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3HqXmlvcGmkaYTpc44hd2ZiaIXtZY4hT0OLWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wPVY2PiEQvF2=	MlHRV2FPT0WU
GT3TKB cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXTPOWJUUW6qaXLpeIlwdiCxZjDoeY1idiCJVEPUT2Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVkvOzV3NE[g{txO	MWHTRW5ITVJ?
HC-1 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWTzcIN1UW6qaXLpeIlwdiCxZjDoeY1idiCKQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2yOE42PTVzIN88US=>	MnzzV2FPT0WU
HAL-01 cell	NHriPWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3z1S2lvcGmkaYTpc44hd2ZiaIXtZY4hUEGOLUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xPU44PTR\|IN88US=>	M12xVHNCVkeHUh?=
HCC1187 cell	MnT5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVjRNnBzUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxNVg4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0{PS56MEWyJO69VQ>?	MkHKV2FPT0WU
DEL cell	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4XGTGlvcGmkaYTpc44hd2ZiaIXtZY4hTEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD12MT65NFg3KM7:TR?=	NWTRfIxsW0GQR1XS
HCC1599 cell	Mn3wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGDObWdKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{G1PVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVMzNjN\|MkWg{txO	MofaV2FPT0WU
DOHH-2 cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml61TY5pcWKrdHnvckBw\iCqdX3hckBFV0iKLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFE4OTlizszN	MXvTRW5ITVJ?
HCC2157 cell	NU\KV3VQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVPibWM4UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OyNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0{Py57OUS2JO69VQ>?	MlfVV2FPT0WU
HCE-4 cell	NGDndYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2D1UGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOHLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNlY1OzlizszN	NEP2cXlUSU6JRWK=
HCE-T cell	MmjkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWDmSJY3UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NU42PjdzNDFOwG0>	NFnWcFRUSU6JRWK=
HEL cell	NW[2cXU2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYrJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OTBwNEe3OkDPxE1?	MU\TRW5ITVJ?
EM-2 cell	M3rNZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2fuZ2lvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wNFAxODFyN{ig{txO	MXzTRW5ITVJ?
HT-144 cell	MonBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHfrRlhKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUG0OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE42OzZyOTFOwG0>	MWPTRW5ITVJ?
EW-16 cell	NXizeHpZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFr3VoVKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlc3OTd6IN88US=>	NWPKT45VW0GQR1XS
IA-LM cell	M2H3N2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUDKeFN{UW6qaXLpeIlwdiCxZjDoeY1idiCLQT3MUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NVIvPDR2NTFOwG0>	M4DLRXNCVkeHUh?=
IST-MEL1 cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFzjc3VKdmirYnn0bY9vKG:oIHj1cYFvKEmVVD3NSWwyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjF\|NEWg{txO	M1XHbHNCVkeHUh?=
IST-MES1 cell	MlX0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnrETY5pcWKrdHnvckBw\iCqdX3hckBKW1RvTVXTNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xQDV3MjFOwG0>	MljtV2FPT0WU
GI-1 cell	NV3nZ5hPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYf2UnRWUW6qaXLpeIlwdiCxZjDoeY1idiCJST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xMlM3OjJizszN	M4rGbXNCVkeHUh?=
IST-SL2 cell	NGfxTG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEm5VmRKdmirYnn0bY9vKG:oIHj1cYFvKEmVVD3TUFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvPTB\|MEKg{txO	Ml65V2FPT0WU
JVM-2 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGpXVS1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1{LkO2Nlg1KM7:TR?=	NWHKOZV{W0GQR1XS
JVM-3 cell	MkPkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmfvTY5pcWKrdHnvckBw\iCqdX3hckBLXk1vMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;M{euNlM{QCEQvF2=	NIfSRWxUSU6JRWK=
KALS-1 cell	NUPCdY1VT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVLRdYg5UW6qaXLpeIlwdiCxZjDoeY1idiCNQVzTMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvODl2OTFOwG0>	NH;4PY9USU6JRWK=
KARPAS-422 cell	M3fSW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHTKcYxKdmirYnn0bY9vKG:oIHj1cYFvKEuDUmDBV{01OjJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwM{O5PVch\|ryP	NWfP[25VW0GQR1XS
JiyoyeP-2003 cell	MmGwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVO4UFJWUW6qaXLpeIlwdiCxZjDoeY1idiCMaYnvfYVRNTJyMEOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUGuO\|M1PjZizszN	NIXaeGxUSU6JRWK=
KARPAS-45 cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2X6Z2lvcGmkaYTpc44hd2ZiaIXtZY4hU0GUUFHTMVQ2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF04NjVzNkexJO69VQ>?	MWrTRW5ITVJ?
KGN cell	MlXqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGDrPVFKdmirYnn0bY9vKG:oIHj1cYFvKEuJTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wNVk1OiEQvF2=	NHrxclJUSU6JRWK=
KLE cell	MnS2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEnuUVNKdmirYnn0bY9vKG:oIHj1cYFvKEuORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6xNVMyPyEQvF2=	MXXTRW5ITVJ?
KNS-42 cell	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnnlTY5pcWKrdHnvckBw\iCqdX3hckBMVlNvNEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUGuNlQ1OTJizszN	NILoN29USU6JRWK=
KNS-81-FD cell	NW\lZWR3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{TJSmlvcGmkaYTpc44hd2ZiaIXtZY4hU06VLUixMWZFKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0zOy5zNE[g{txO	M3P5fXNCVkeHUh?=
KP-N-YS cell	NVvWPHBwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYXJcohq[mm2aX;uJI9nKGi3bXHuJGtRNU5vWWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUGyMlkzQDNizszN	MoTQV2FPT0WU
HOP-62 cell	NXvh[GFQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF\BNXFKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xOTh\|NDFOwG0>	NYPhdlFLW0GQR1XS
KURAMOCHI cell	NE\0bZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUT1SWlLUW6qaXLpeIlwdiCxZjDoeY1idiCNVWLBUW9EUEliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMEO0PFch\|ryP	NGLNUFhUSU6JRWK=
HUTU-80 cell	NGT4XppIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXHJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuN\|E1OiEQvF2=	NVvRT5Z{W0GQR1XS
LAMA-84 cell	M4HjfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{j2UmlvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xODByMEOyNFch\|ryP	NIXiVZZUSU6JRWK=
LB1047-RCC cell	M17X[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHLPTmdKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMEC5PFg4KM7:TR?=	MnT6V2FPT0WU
LB2518-MEL cell	Mn;xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{LvUGlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ{NUG4MW1GVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC5zNEG2NkDPxE1?	NF\Cb4pUSU6JRWK=
LB373-MEL-D cell	MmXVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4rMXmlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ\|N{OtUWVNNURiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwOEK1NFgh\|ryP	NYe5XGlIW0GQR1XS
LB771-HNC cell	MmHES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGHDc21KdmirYnn0bY9vKG:oIHj1cYFvKEyEN{exMWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:Oi53N{W1NUDPxE1?	MX\TRW5ITVJ?
LB996-RCC cell	NFjtS4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGxDQTl4LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xODl7MUKg{txO	Mo[wV2FPT0WU
LC-2-ad cell	NHGxO5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGXURlVKdmirYnn0bY9vKG:oIHj1cYFvKEyFLUKtZYQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvODJ3OE[g{txO	MmjQV2FPT0WU
J-RT3-T3-5 cell	M164V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX;J[ph[UW6qaXLpeIlwdiCxZjDoeY1idiCMLWLUN{1VOy13IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD16Lkm2OVI6KM7:TR?=	NXHzU4czW0GQR1XS
LP-1 cell	NV\YNWRHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWXoU5pnUW6qaXLpeIlwdiCxZjDoeY1idiCOUD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME23MlU1Pzh{IN88US=>	NVq4W\|JCW0GQR1XS
K-562 cell	NYLCU242T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUDJcohq[mm2aX;uJI9nKGi3bXHuJGsuPTZ{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCwNFAxODJ4NU[g{txO	NWDDPFFOW0GQR1XS
LS-123 cell	NY[5[nBHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NImyTYtKdmirYnn0bY9vKG:oIHj1cYFvKEyVLUGyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4yPDB4NDFOwG0>	NILncGZUSU6JRWK=
K5 cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHTrcVhKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkG2OFg6KM7:TR?=	NYHab\|RVW0GQR1XS
LS-411N cell	NF[0UWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MorZTY5pcWKrdHnvckBw\iCqdX3hckBNWy12MUHOJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME20PE41PzR6IN88US=>	MmnzV2FPT0WU
KG-1 cell	NWPnU5Y2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIjFfGZKdmirYnn0bY9vKG:oIHj1cYFvKEuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUSuOlA5PDVizszN	NV;xU\|RZW0GQR1XS
KINGS-1 cell	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml7mTY5pcWKrdHnvckBw\iCqdX3hckBMUU6JUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlE3PjZ4IN88US=>	NVvoZ2U4W0GQR1XS
LXF-289 cell	NFrEcYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1rmbmlvcGmkaYTpc44hd2ZiaIXtZY4hVFiILUK4PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xOzl3NjFOwG0>	MkO4V2FPT0WU
MC116 cell	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3\Ne2lvcGmkaYTpc44hd2ZiaIXtZY4hVUNzMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNVE1OSEQvF2=	NXu5XYtQW0GQR1XS
KS-1 cell	NIX6OG9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYC3[lg2UW6qaXLpeIlwdiCxZjDoeY1idiCNUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlAzPzNizszN	NVf6dHhlW0GQR1XS
KU812 cell	M{fPVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4Szd2lvcGmkaYTpc44hd2ZiaIXtZY4hU1V6MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNVE5QDNizszN	NYDpb5l7W0GQR1XS
MEG-01 cell	NGDwT2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEm0U4RKdmirYnn0bY9vKG:oIHj1cYFvKE2HRz2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xODByMEm4NFUh\|ryP	NFyzcZdUSU6JRWK=
MFH-ino cell	NF\3V4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4fzSmlvcGmkaYTpc44hd2ZiaIXtZY4hVU[KLXnuc{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xPDd{NDFOwG0>	NWDSO4VnW0GQR1XS
L-540 cell	MkSwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXfJcohq[mm2aX;uJI9nKGi3bXHuJGwuPTRyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1zNT6wOlcyKM7:TR?=	NHPpfo1USU6JRWK=
MHH-NB-11 cell	NYfvWmlUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUfuWVBEUW6qaXLpeIlwdiCxZjDoeY1idiCPSFitUmIuOTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTR\|LkC4NVgh\|ryP	M2D3THNCVkeHUh?=
MMAC-SF cell	MnzlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIDUO3pKdmirYnn0bY9vKG:oIHj1cYFvKE2PQVOtV2Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVgvPzl\|MEeg{txO	NH7NVXRUSU6JRWK=
LB2241-RCC cell	M3jlVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmjJTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF06NjB{MEGyJO69VQ>?	NHWyb5dUSU6JRWK=
LB831-BLC cell	NE\ofFFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHXvN2xKdmirYnn0bY9vKG:oIHj1cYFvKEyEOEOxMWJNSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC5yNE[wPUDPxE1?	Ml7YV2FPT0WU
MOLT-16 cell	M1vnSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXrJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUK5MlYzQTJizszN	MXLTRW5ITVJ?
LC-1F cell	NEDhRlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NV;mem9vUW6qaXLpeIlwdiCxZjDoeY1idiCOQz2xSkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NlcvOzJ2NTFOwG0>	NGC0RVJUSU6JRWK=
MOLT-4 cell	MkLhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFruVJBKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NlYvPjd3MzFOwG0>	MlqwV2FPT0WU
MZ1-PC cell	MkHES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYHlVllZUW6qaXLpeIlwdiCxZjDoeY1idiCPWkGtVGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvODNzMUmg{txO	M1LIcHNCVkeHUh?=
MONO-MAC-6 cell	M1P2SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2\ybWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:QTz3NRWMuPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:QC5{N{C2OkDPxE1?	MXXTRW5ITVJ?
MZ2-MEL cell	M{ftXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4K2PWlvcGmkaYTpc44hd2ZiaIXtZY4hVVp{LV3FUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4zQDV\|NzFOwG0>	NFmxRVNUSU6JRWK=
MPP-89 cell	NFP6ZY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVPxXItsUW6qaXLpeIlwdiCxZjDoeY1idiCPUGCtPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvODRyNEmg{txO	M2jydnNCVkeHUh?=
MZ7-mel cell	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYnJcohq[mm2aX;uJI9nKGi3bXHuJG1bPy2vZXygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuOFc6OTFizszN	NHzhZ5FUSU6JRWK=
LOXIMVI cell	M4jQTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGDsSJZKdmirYnn0bY9vKG:oIHj1cYFvKEyRWFnNWmkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvOzF3MEOg{txO	M2TUZnNCVkeHUh?=
NALM-6 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NW\TcGhOUW6qaXLpeIlwdiCxZjDoeY1idiCQQVzNMVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvOTl{OUWg{txO	NYL3WGY2W0GQR1XS
NB13 cell	NV3yRWZkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mn23TY5pcWKrdHnvckBw\iCqdX3hckBPSjF\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1zOT60PFc4KM7:TR?=	MmXZV2FPT0WU
NB5 cell	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUHJcohq[mm2aX;uJI9nKGi3bXHuJG5DPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OS5\|OUiyO{DPxE1?	MWnTRW5ITVJ?
NB17 cell	M3yxUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{XWWWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;Mz62N\|g1PyEQvF2=	NYTl[\|R{W0GQR1XS
NCCIT cell	NYHvOmYzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1;TPWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOFSWSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUKuPFY3OTZizszN	NXfVVnM4W0GQR1XS
NB69 cell	MoXZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mkn0TY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkG0OFM3KM7:TR?=	M3zBe3NCVkeHUh?=
NCI-H1304 cell	M13BT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NH:4bY1KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVMxPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OjhwMU[yPEDPxE1?	M2nPRXNCVkeHUh?=
NCI-H1395 cell	M13iVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlPOTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGzPVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVQzNjBzNkOg{txO	NVe1ZpY2W0GQR1XS
MHH-PREB-1 cell	NFTPNWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mn3qTY5pcWKrdHnvckBw\iCqdX3hckBOUEhvUGLFRk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjd2NE[5JO69VQ>?	NXHJU5l{W0GQR1XS
MLMA cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkPBTY5pcWKrdHnvckBw\iCqdX3hckBOVE2DIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkG0NFMzKM7:TR?=	MlzDV2FPT0WU
MN-60 cell	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEDrXFhKdmirYnn0bY9vKG:oIHj1cYFvKE2QLU[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xOU4yQTd7IN88US=>	NG\DcGVUSU6JRWK=
MV-4-11 cell	M2S1d2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYK4dld[UW6qaXLpeIlwdiCxZjDoeY1idiCPVj20MVEyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF01NjN4NEW0JO69VQ>?	NX;4UIxKW0GQR1XS
NB6 cell	MlmzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVPteFNHUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUmuPVIzPTlizszN	M2Pkb3NCVkeHUh?=
NCI-H1355 cell	M3HYWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlrVTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGzOVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvOTFyMkig{txO	NWrDRmJRW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416) ; PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. cleaved caspase 3 ; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control. p-FAK/p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.	23049975 20145167 23721490
Growth inhibition assay	Cell viability; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	- Collapse Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- Collapse

Solubility (25°C)

In vitro	DMSO	21 mg/mL warmed (41.5 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+dd H2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib Monohydrate SDF

Molecular Weight	506.02
Formula	C₂₂H₂₈ClN₇O₃S
CAS No.	863127-77-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	BMS-354825 Monohydrate
Smiles	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO.O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04933526	Not yet recruiting	Drug: Flumatinib\|Drug: Dasatinib	Chronic Myeloid Leukemia in Chronic Phase	Shenzhen Second People''s Hospital	July 1 2021	Phase 4
NCT04925648	Not yet recruiting	Drug: Dasatinib\|Drug: Darolutamide	Metastatic Prostate Cancer	St Vincent''s Hospital Sydney	July 1 2021	Phase 2
NCT04063124	Recruiting	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	February 14 2020	Phase 1\|Phase 2
NCT04155411	Recruiting	Drug: Dasatinib	Dasatinib\|BCR-ABL\|Chronic Myeloid Leukemia	Shenzhen Second People''s Hospital	December 1 2019	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the difference between S1021 and S7782?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

Src Signaling Pathway Map

Related Src Products

SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Defactinib (VS-6063) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
Dasatinib (BMS-354825)

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
KX2-391 (Tirbanibulin)

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 (AGL 1872, EI 275) is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 (KIN001-112, KIN112, Dual LCK/SRC inhibitor) is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib Monohydrate